PDS Biotechnology director granted 54,876 stock options

PDS Biotechnology Corp director Stephen C. Glover received a grant of employee stock options for 54,876 shares on January 12, 2026.

Rhea-AI Filing Summary

PDS Biotechnology Corp director Stephen C. Glover received a grant of employee stock options for 54,876 shares on January 12, 2026. The options have an exercise price of $0.00 per share and represent a right to buy the company’s stock.

According to the filing, the entire stock option grant vests and becomes fully exercisable on the first anniversary of the grant date, as long as Glover continues to serve as a director through that date. After this grant, he directly holds options covering 54,876 shares.

Insider Trade Summary

Grant/Award: 54,876 shares

Grant/Award 1 txn

Insider Glover Stephen C.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	54,876	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 54,876 contracts (Direct)

Footnotes (1)

1. F1. The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PDSB director Stephen C. Glover acquire in this Form 4 filing?

Stephen C. Glover received an employee stock option grant for 54,876 shares of PDS Biotechnology Corp common stock. The options were awarded at an exercise price of $0.00 per share, representing a right to buy shares subject to vesting conditions described in the filing.

When do Stephen C. Glover’s PDSB stock options vest?

The stock options granted to Stephen C. Glover vest in full on the first anniversary of the grant date. Vesting is conditional on his continued service as a director of PDS Biotechnology Corp through that one-year anniversary, as specified in the footnote.

How many PDSB shares are covered by Stephen C. Glover’s new options?

The grant covers options for 54,876 shares of PDS Biotechnology Corp common stock. After this transaction, the Form 4 states that Glover directly holds options over a total of 54,876 shares, reflecting this entire award.

What is the exercise price of Stephen C. Glover’s PDSB stock options?

The reported exercise price for Stephen C. Glover’s employee stock options is $0.00 per share. This means he did not pay anything to receive the options themselves, although exercising them in the future will follow the plan’s terms.

Is Stephen C. Glover’s ownership in PDSB direct or indirect after this grant?

The Form 4 reports that Stephen C. Glover holds these options as a direct owner. The ownership code is listed as “D” for direct, and no separate entity or indirect ownership structure is referenced in the footnote for this transaction.

What role does Stephen C. Glover have at PDS Biotechnology Corp (PDSB)?

The filing identifies Stephen C. Glover as a director of PDS Biotechnology Corp. His stock option award is tied to his board service, with vesting conditioned on his continued service to the company as a director for one year from the grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 06:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Glover Stephen C.

(Last) (First) (Middle)

C/O PDS BIOTECHNOLOGY CORPORATION

303A COLLEGE ROAD EAST

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PDS Biotechnology Corp [ PDSB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$0.98	01/12/2026		A		54,876		(1)	01/12/2036	Common Stock	54,876	$0	54,876	D

Explanation of Responses:

1. The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date.

	/s/ Spencer Brown, as Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.